View Older Stories View More Recent Stories
-
UBS Reiterates Buy Rating on Eli Lilly (LLY) Following Strong Q4, Upside Guidance
-
HSBC downgrades Eli Lilly, says shares are 'priced to perfection'
-
HSBC Downgrades Eli Lilly (LLY) to Reduce
-
Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
-
RBC: 'Our focus for LLY remains on the pending Orfo approval and subsequent launch'
-
Jefferies Reiterates Buy Rating on Eli Lilly (LLY): 'early oral Wegovy launch is directionally encouraging'
-
Eli Lilly to invest $3 billion in China, seeks approval for new GLP-1 drug
-
Hims & Hers hires ex-Eli Lilly PR chief Beiser as top communications officer
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
TD Cowen: 'Wegovy Injection may be declining'
-
Amazon Pharmacy adds Eli Lilly's Zepbound KwikPen with $299 pricing
-
Deutsche Bank Reiterates Buy Rating on Eli Lilly (LLY) following aggregate scripts
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY): "We see ~7% upside to '26 M+Z ests"
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY) following Employer Connect launch
-
Lilly launches employer platform for obesity drug access with 15 administrators
-
FDA issues 30 warning letters to telehealth firms over GLP-1 claims
-
CHMP recommends Eli Lilly's Olumiant for teens with severe hair loss
-
Eli Lilly's orforglipron outperforms oral semaglutide in diabetes trial
-
Bernstein Weighs In on Eli Lilly (LLY) Amid 'Risk of a Price War'
-
RBC Capital Starts Eli Lilly (LLY) at Outperform
-
BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'
-
Eli Lilly falls 2% on Novo Nordisk price cut plans
-
Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
-
Novo Nordisk To Cut Ozempic List Price By 34% - WSJ
-
Eli Lilly launches multi-dose KwikPen for Zepbound weight management drug
-
Novo Nordisk's CagriSema fails to match tirzepatide in obesity trial
-
Novo Nordisk (NVO) -13% after 'worst case' REDEFINE-4 readout; LLY +4%
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into share price up before the bell
-
Barclays Starts Eli Lilly (LLY) at Overweight
-
Lilly's Omvoh shows sustained remission in Crohn's disease study
-
Eli Lilly's psoriasis and obesity drugs show superior results in trial
-
This pharma stock is 'poised to outperform in 2026,' Wolfe says
-
Freedom Capital Markets Upgrades Eli Lilly (LLY) to Buy
-
UBS Reiterates Buy Rating on Eli Lilly (LLY), Bullish on Orfo
-
BMO Capital: 'Eli Lilly (LLY) to Expand Into in Vivo CAR-T Space With Acquisition of Orna'
-
Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY) Following Expert Call
-
Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put
-
FDA moves to restrict copycat GLP-1 weight loss drugs
-
Bernstein on Eli Lilly (LLY): 'Raising expectations into 2026'
-
TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
-
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
-
Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
-
Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
-
Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
-
Eli Lilly (LLY) PT Raised to $1,300 at JPMorgan
-
Eli Lilly (LLY) PT Raised to $1,293 at BofA Securities
-
Eli Lilly (LLY) PT Raised to $1,281 at Truist Securities
-
TD Cowen: 'Eli Lilly (LLY) Confident Oral GLP-1s Will Expand Mkt'
